10+
installations · ≈16
—
0 notes
2025-03-13
première sortie
2026-02-03
dernière mise à jour
Description
Study for Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC
This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
Nouveautés
Bug fixes and performance improvements
Détails
| Version | 5.4.1100.1-prod |
|---|---|
| Version Android minimale | 8.0 |
| Avis | 0 |
| Disponible dans | Samoa américaines, Autriche, Australie, Îles Åland, Belgique, Bulgarie, Saint-Barthélemy, Brésil, Canada, Suisse, Chili, Chine et 53 de plus |
| Coordonnées du développeur | dans l'offre Business |
| Données collectées | 2026-11-15 |
Ces données dans l'API
La fiche complète en JSON coûte 1 jeton.
curl -H "X-API-Key: YOUR_KEY" \ "https://apkapi.com/api/v1/app?id=com.medable.lilly.jzqh"
